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Abstract 
We report the case of a 26-year-old male who presented with acute pancreatitis during 
the course of treatment for pancolitic ulcerative colitis (UC) with a time-dependent 
mesalazine formulation, prednisolone and azathioprine (AZA). Despite a review of his 
clinical history and various tests, the cause of pancreatitis could not be determined. 
Since drug-induced pancreatitis was considered possible, administration of the 
time-dependent mesalazine preparation and AZA was discontinued, and conservative 
treatment for acute pancreatitis was performed. The pancreatitis promptly improved 
with these treatments, but drug lymphocyte stimulation test (DLST) for both the 
time-dependent mesalazine formulation and AZA was negative. A pH-dependent 
mesalazine formulation was given for maintenance therapy of UC. Subsequently, as the 
pancreatitis relapsed, drug-induced pancreatitis was strongly suspected. Administration 
of mesalazine was discontinued, and pancreatitis was smoothly in remission by 
conservative treatment. According to the positive DLST result for the pH-dependent 
mesalazine formulation and the clinical course, a diagnosis of pH-dependent 
mesalazine-induced pancreatitis due to this formulation was made. During the clinical 
course of UC, occurrence of drug-induced pancreatitis must always be considered. Case Rep Gastroenterol 2011;5:610–616 
DOI: 10.1159/000333605 
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Introduction 
Pancreatitis is known to occur more frequently in patients with ulcerative colitis (UC) 
than in healthy individuals. The incidence of acute pancreatitis is 1.5–3.5% in patients 
with inflammatory bowel disease [1, 2]. Pancreatitis is an extraintestinal complication of 
UC. In addition, drug-induced pancreatitis is caused by adverse effects of various drugs 
used to treat UC, so it might be difficult to distinguish these two causes of pancreatitis in 
patients with UC. Azathioprine (AZA), prednisolone (PSL) and mesalazine, which are 
usually taken for inflammatory bowel disease, have been reported to be drugs that can 
possibly cause pancreatitis. Mesalazine is the most widely used first-choice drug for 
treatment of inflammatory bowel disease. It is a bowel-specific aminosalicylate drug and 
is metabolized in the gut, and thereby has fewer systemic side effects. However there are 
some reports of acute pancreatitis caused by this drug [3]. In Japan, two types of 
mesalazine with different outer chemical coating are used: time-dependent (Pentasa) 
and pH-dependent mesalazine (Asacol). 
Presented in this report is a case of acute pancreatitis occurring during the course of 
treatment for UC with both time- and pH-dependent mesalazine. A final diagnosis of 
mesalazine-induced acute pancreatitis was made due to the clinical course and laboratory 
data which included the drug lymphocyte stimulation test (DLST). 
Case Report 
The patient was a 26-year-old male. He had been healthy, but consulted our hospital with a chief 
complaint of bloody stools for 6 months, and was hospitalized due to severe anemia (hemoglobin 
5.4 g/dl). Endoscopic investigation revealed moderate active pancolitis-type UC (fig. 1a). Treatment 
with both an intensive intravenous regimen of 60 mg (1 mg/kg body weight) PSL per day and 
leukocytapheresis was carried out. His symptoms began to be alleviated, his laboratory data improved, 
and the dosage of PSL was gradually reduced. As maintenance therapy, oral administration of a 
time-dependent mesalazine preparation at 4,000 mg/day was started. Just after decreasing the dosage of 
PSL to 15 mg, his symptoms, including bloody stools and frequent diarrhea, appeared again. As 
recurrence of UC was suspected, the dosage of PSL was increased and AZA was added at 50 mg/day. His 
symptoms of bloody stools and frequent diarrhea both improved with these additional therapies. 
However, he asked for emergency consultation with sudden abdominal pain and a high fever 1 month 
after receiving these additional therapies. He was admitted with a diagnosis of mild acute pancreatitis 
because of his high serum amylase (792 IU/l) and the finding of a swollen pancreas on abdominal 
contrast-enhanced CT (fig. 2a, b). Since drug-induced pancreatitis is possible with time-dependent 
mesalazine formulation and AZA, both drugs were discontinued despite the negative results of the 
DLST. He was discharged from our hospital as his symptoms had completely disappeared and there 
were no abnormal findings on both abdominal ultrasonographic examination and magnetic resonance 
cholangiopancreatography. After discharge, administration of low-dose salazosulfapyridine was started 
for maintenance therapy of UC. That formulation was switched to a pH-dependent mesalazine 
formulation at 2,400 mg/day because liver damage due to salazosulfapyridine was suspected after several 
weeks. After this change in drug regimen, abdominal pain gradually appeared. After 2 weeks of 
treatment with pH-dependent mesalazine, serum amylase increased again to 1,555 IU/l. A second 
episode of acute pancreatitis was then diagnosed, and the patient was readmitted. Abdominal 
contrast-enhanced CT images revealed enlargement of the entire pancreas, but no turbidity in the 
adipose tissue around the pancreas (fig. 2c). His clinical course (fig. 3) suggested drug-induced 
pancreatitis due to the pH-dependent mesalazine formulation because his acute pancreatitis became 
worse just after the change of drug regimen. Conservative treatment resulted in rapid improvement in 
his symptoms and laboratory data, with normalization of amylase 4 days after drug discontinuation. 
The DLST of the pH-dependent mesalazine preparation was strongly positive with a stimulation index 
of 426% compared to normal controls. According to the DLST results and his clinical course, 
drug-induced pancreatitis due to this formulation was suspected. After discharge, the patient was Case Rep Gastroenterol 2011;5:610–616 
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followed up with low-dose PSL, with no recurrence of pancreatitis noted since then (table 1). 
Colonoscopy was performed at each of the two episodes of pancreatitis, but no exacerbation of UC was 
noted at either time point (fig. 1b, c). 
Discussion 
The complication of pancreatitis in UC could possibly be due to an extraintestinal 
complication of UC and/or drug-induced pancreatitis due to certain drugs that are used 
for treatment of UC. Though the mechanisms of pancreatitis as an extraintestinal 
complication of UC remain unclear, there are some reports that have suggested possible 
mechanisms: malnutrition in UC, activation of trypsinogen due to intestinal bacteria, 
existence of a local circulatory disorder due to stimulation of the sympathetic nervous 
system, stimulation in cavities around the pancreatic acinus by proteases and cytokines 
derived from the colon mucosa via the portal lymphatic system, and exocrine disorders 
associated with an increase in the viscosity of pancreatic juice due to intestinal paralysis or 
dehydration [4–6]. On the other hand, UC may be associated with autoimmune 
pancreatitis from the consideration of autoimmune disease [7] and involvement of 
anti-carbonic anhydrase II antibody [8]. The occurrence of autoimmune pancreatitis is 
known to be strongly related to the disease activity of UC. 
Among the drugs used for treatment of UC, mesalazine, PSL, and immunomodulators 
such as AZA are well known to cause drug-induced pancreatitis. The pathogenic 
mechanism of drug-induced pancreatitis remains unclear; however, some reasons, such 
as direct toxicity and allergic mechanism, have been proposed [9, 10]. Although the 
mechanism of pancreatitis due to mesalazine is also unclear, an allergic mechanism 
is considered to be involved in its formation, as it often occurs a few days after the 
beginning of administration of these drugs [11] and occurs within 1 month in 71.4% 
of patients [12]. Mallory and Kern [9] reported that the diagnosis of drug-induced 
pancreatitis requires (1) occurrence of the condition during treatment with the 
drug, (2) resolution by discontinuation of administration, and (3) recurrence on 
readministration (readministration of the suspicious drug being difficult). The DLST 
is an in vitro test of type IV allergic reactions to drugs, so the test is both safe and useful 
as an accessory diagnostic tool for drug-induced pancreatitis. However, DLST results 
should be evaluated carefully and considering the patient’s clinical course, as 
false-negatives or false-positives may be influenced by many factors such as antigen 
exposure duration to DLST and some concomitant medications [13]. 
In this case, the second episode of pancreatitis was diagnosed as drug-induced 
pancreatitis due to a pH-dependent mesalazine formulation, because the disease was 
diagnosed 14 days after the beginning of its administration, it resolved immediately 4 days 
after its discontinuation, and the DLST was positive. From this result and the clinical 
course, the first episode of pancreatitis was suspected to be caused by a time-dependent 
mesalazine formulation since the DLST of this drug was negative. AZA could also have 
been a potential drug that caused pancreatitis despite the negative DLST in the present 
case. AZA-induced pancreatitis is considered to be an allergic disorder and its incidence is 
2.3%, higher than mesalazine-induced pancreatitis [10]. PSL can also cause pancreatitis 
[9], however it was administered continuously throughout the present course, and was 
therefore considered unlikely to have been related to pancreatitis. Case Rep Gastroenterol 2011;5:610–616 
DOI: 10.1159/000333605 
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The pathogenic mechanism of mesalazine-induced pancreatitis remains unknown. 
The proposed pathogenic mechanism is increased permeability of the pancreatic duct 
due to the direct effect of salicylic acid [14]. Although there is a chemical similarity 
between 5-aminosalicylic acid (5-ASA) and salicylic acid, the former should not directly 
stimulate the pancreatic ducts, since it is delivered as an active drug only in the terminal 
ileum and colon. It is therefore postulated that systemic absorption might occasionally 
occur for 5-ASA in high doses, and therefore could possibly cause toxicity in the pancreas 
[15]. On the other hand, even low blood levels of salicylate may be involved in acute 
pancreatitis in individual subjects in the setting of a hypersensitivity reaction, similar 
to Reye’s syndrome [14]. In the present case, no information on the drug serum 
concentration was available. However, it was confirmed by the lymphocyte proliferation 
test that the present patient had an allergic reaction to 5-ASA, considering his clinical 
course. Time- and pH-dependent mesalazine formulations differ only in their coating 
material and have the same active component. Since the courses of pancreatitis caused by 
the two formulations were similar according to the reports to date [3, 12], mesalazine 
itself might be considered to cause pancreatitis. 
Conclusions 
During the clinical course of UC, occurrence of acute pancreatitis should be 
monitored carefully. Once acute pancreatitis has occurred, drug-induced pancreatitis 
must always be considered a differential diagnosis in addition to exacerbation of the 
primary inflammatory bowel disease. When the possibility of drug-induced pancreatitis 
is considered, discontinuation of its administration must be weighed. Further discussion 
of the safety of mesalazine preparations and the pathogenic mechanism of drug-induced 
pancreatitis is needed. 
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Table 1. Laboratory data 
Biochemistry     Peripheral  blood   
AST, IU/l  >00.17   WBC,  /μl  11,600 
ALT, IU/l  >00.32        Neutrophils, %  0071.0 
LDH, IU/l  >0.136        Lymphocytes, %  0014.4 
ChE, U/l  >0.267        Mono, %  0007.4 
T-bil, mg/dl  >000.7        Eosino, %  0006.9 
γGTP, IU/l  >00.64        Baso, %  0000.3 
AMY, IU/l  >1,555   RBC  (×10
6/μl)  00.464 
Lipase, IU/l  >5,651   Hb,  g/dl  0014.4 
TP, g/dl  >007.5   Ht,  %  0043.4 
Alb, g/dl  >004.0   MCV,  fl  0093.5 
BUN, mg/dl  >000.7   MCH,  pg  0031.0 
Cr, mg/dl  >00.79   MCHC,  %  0033.2 
Na, mmol/l  >0.139   Plt,  ×10
4/μl  0025.8 
K, mmol/l  >003.8   Coagulation   
Cl, mmol/l  >0.102   PT,  %  000.93 
CRP, mg/dl  >03.49   APTT,  s  0030.5 
ESR1Hr, mm  >00.33   Fbg,  mg/dl  00.432 
IgG, mg/dl  >1,197      
IgA, mg/dl  >0.182      
IgM, mg/dl  >00.81      
Elastase1, ng/dl  >5,000       
PSTI, ng/ml  >109.0      
PLA2, ng/dl  >3,990      
IgG4, mg/dl  >033.8      
 
 
 
 
 
Fig. 1. Lower gastrointestinal endoscopy. a At the onset of UC. Sigmoid colon. Coarseness of the 
mucosa, disappearance of blood vessels seen through the mucosa, reddening, and erosion are observed 
continuously from the rectum to the ascending colon. b At the onset of the initial episode of 
pancreatitis. Sigmoid colon. Blood vessels are observed clearly through the mucosa, and no sign of 
inflammation is noted. c At the recurrence of pancreatitis. Sigmoid colon. No sign of inflammation is 
noted, as in b. 
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Fig. 2. Abdominal contrast-enhanced CT. a At the onset of UC. No abnormalities are noted in the 
pancreas. b At the onset of the initial episode of pancreatitis. The pancreas is mildly enlarged (arrow). 
c At the recurrence of pancreatitis. The pancreas is mildly enlarged, as in b (arrow). 
 
 
 
Fig. 3. Clinical course. 
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